{"id":"W2766291043","doi":"10.1111/jdv.14647","title":"Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nexus Clinical Research (Canada); SKiN Health; Merck Canada Inc. (Canada); Lynde Centre for Dermatology; Recyc PHP (Canada); Innovation Initiatives Ontario North; Manitoba Beekeepers' Association; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Novo Nordisk; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Celgene; Novartis; AbbVie; Sanofi; Merck; GlaxoSmithKline; LEO Pharma Research Foundation; Pfizer; Boehringer Ingelheim; Amgen; Eli Lilly and Company; DUSA Pharmaceuticals; Abbott Fund","keywords":"Medicine; Apremilast; Psoriasis; Dermatology; Placebo; Randomized controlled trial; Double blind; Palmoplantar pustulosis; Internal medicine; Alternative medicine; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005207834,0.001223532,0.003836863,0.0006029285,0.0004487707,0.001107409,0.0009882372,0.0019555,0.006621538],"category_scores_gemma":[0.003346752,0.0007980369,0.002617116,0.0005159678,0.001045144,0.0009647323,0.0003479968,0.001578963,0.0007062881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004526441,"about_ca_system_score_gemma":0.0009701082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003589472,"about_ca_topic_score_gemma":0.0007686445,"domain_scores_codex":[0.997881,0.001344682,0.0002175444,0.0002132557,0.0002195157,0.0001239746],"domain_scores_gemma":[0.9979419,0.000874433,0.0005247364,0.0001421804,0.0001650155,0.0003516948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9669799,0.006324033,0.0003388792,0.002077866,0.001588346,0.00004376534,0.00003426196,0.0001280892,0.003658412,0.00006426575,0.0003829941,0.01837907],"study_design_scores_gemma":[0.962223,0.03524075,0.001142408,0.00005355239,0.0006469883,0.00003702913,0.000008911245,0.0001107159,0.0002060503,0.00003991851,0.0002815941,0.00000918405],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9526663,0.03063372,0.001953225,0.001038449,0.001175096,0.008513538,0.001256299,0.0002401908,0.002523226],"genre_scores_gemma":[0.9692582,0.01585449,0.003258216,0.001312987,0.001170184,0.005784757,0.001002013,0.00003573609,0.00232337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006621538,"threshold_uncertainty_score":0.027542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0427613775513459,"score_gpt":0.2904193061054218,"score_spread":0.2476579285540759,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}